Direct employment at Novartis is projected to rise by roughly 700 positions as a result of the expansion. The company also anticipates more than 3,000 indirect jobs will be generated across suppliers and service providers linked to the project by 2030. Roles will span engineering, quality assurance, production, and support functions, with recruitment scheduled to accelerate as facility construction progresses.
The investment follows a preliminary agreement reached last week between the United States and Switzerland to reduce U.S. import tariffs on Swiss goods to 15 % from the previous 39 % rate. Under that framework, Swiss corporations collectively pledged to allocate $200 billion to projects in the United States by the end of 2028. Novartis’ new hub constitutes a significant portion of that commitment.
In a statement, the company emphasized that enlarging its North Carolina footprint fits into a long-term goal of bolstering capacity for complex biologic treatments and advanced sterile packaging. While Novartis currently manufactures certain products in the United States, the added facilities are expected to bring a larger share of the firm’s global portfolio under domestic production standards, including stringent requirements for temperature-controlled handling and contamination control.
Durham and Morrisville were selected on the basis of existing Novartis infrastructure, access to a skilled workforce, and proximity to specialized suppliers. The region hosts a concentration of pharmaceutical and biotech activity, offering a deep labor pool in life-science disciplines. The company said collaboration with local educational institutions will be central to workforce development as it prepares to staff the new operations.
The planned construction aligns with national efforts to reinforce pharmaceutical supply chains after recent disruptions. According to the Office of the United States Trade Representative, bilateral trade with Switzerland has historically included a substantial share of pharmaceutical and medical products, making the sector a focal point for investment policies.
Novartis did not disclose specific capital allocations for each facility but confirmed that the combined projects make up a large share of the $23 billion it intends to spend in the United States through 2030. The remainder of the funds will be used for technology upgrades, research collaborations, and other site improvements across the company’s American network.
Regulatory filings, environmental assessments, and construction permits for the North Carolina sites are scheduled to be submitted in stages beginning next year. Novartis stated that it will comply with federal and state guidelines on environmental management, worker safety, and community engagement throughout the build-out period.
Once the hub is fully operational, the company expects shorter production lead times, greater flexibility in responding to market demand, and simplified logistics for distributing medicines across the country. Novartis plans to integrate digital monitoring systems and advanced analytics to track production metrics in real time, aiming to maintain consistent product quality and meet U.S. regulatory requirements.
The company noted that local suppliers stand to benefit from increased demand for raw materials, packaging components, and specialized equipment. Economic development agencies in North Carolina estimate that related business activities—including construction services, utilities, and transportation—will add a significant multiplier effect to regional growth, although precise estimates were not provided in the Novartis statement.
With the North Carolina expansion, Novartis will join several multinational drugmakers that have recently announced new or enlarged U.S. facilities, responding to policy incentives that encourage domestic manufacturing. The company indicated that further announcements regarding additional U.S. projects could follow as its five-year investment plan advances.
Crédito da imagem: Reuters/Arnd Wiegmann
